GOSS
A cash raise with a catch
Gossamer Bio just unveiled a structured private placement that could deliver up to $250 million in gross proceeds. Sounds nice, right? Well, the money comes with a very biotech-flavored plot twist: a big chunk is tied to seralutinib’s trip through the FDA maze.
The money trail
Here’s the setup:
- About $25 million lands at the initial closing
- Roughly $125 million only kicks in if the FDA accepts seralutinib’s NDA for pulmonary arterial hypertension
- Another $100 million is waiting at the finish line if the FDA actually approves it
So yes, this is financing. But it’s also a confidence test. The investors are basically saying, “We’ll help fund the story, but only if the plot keeps moving.”
Why investors care
Seralutinib is Gossamer’s lead shot on goal, and the company says it plans to file the NDA in September. That means the next few months could be a live drama of regulatory milestones, with the stock likely reacting to every FDA breadcrumb along the way.
The good news: the raise could help extend the cash runway. The less-good news: milestone-linked financing usually means dilution risk is lurking in the bushes, waving at shareholders like an uninvited ex.
Big picture: Gossamer isn’t just raising money — it’s trying to buy time, and the FDA gets a vote on how expensive that time becomes.